Stay updated on Acalabrutinib vs Ibrutinib in CLL Clinical Trial
Sign up to get notified when there's something new on the Acalabrutinib vs Ibrutinib in CLL Clinical Trial page.

Latest updates to the Acalabrutinib vs Ibrutinib in CLL Clinical Trial page
- Check7 days agoChange DetectedThe page revision was updated from v3.5.4 to v3.5.5, indicating a newer version of the page content.SummaryDifference0.0%

- Check14 days agoChange DetectedNew May 2026 update dates were added to the Study Record Dates (2026-05-22, 2026-05-27, and 2026-05), while older March 2026 dates (2026-03-10, 2026-03-27, and 2026-03) were removed.SummaryDifference0.1%

- Check21 days agoNo Change Detected
- Check28 days agoChange DetectedThe page's revision tag was updated from v3.5.3 to v3.5.4, indicating a minor version update.SummaryDifference0.0%

- Check42 days agoChange DetectedA new page revision tag v3.5.3 was added, replacing the previous v3.5.2. This is a metadata-level change that does not alter visible content or user interactions.SummaryDifference0.0%

- Check56 days agoChange Detected- Page revision label updated from v3.5.0 to v3.5.2. No substantive changes to study details or content are evident.SummaryDifference0.0%

- Check71 days agoChange DetectedThe study now lists 130 locations and has removed Istanbul, Türkiye. A link to the Genetic and Rare Diseases Information Center is added, and the term B-cell chronic lymphocytic leukemia is included.SummaryDifference0.3%

Stay in the know with updates to Acalabrutinib vs Ibrutinib in CLL Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Acalabrutinib vs Ibrutinib in CLL Clinical Trial page.